RD2D3

RD2D3 is an all-D-enantiomeric linear tandem peptide developed for the treatment of Alzheimer's disease. It was designed by researchers at Forschungszentrum Jülich as a hybrid molecule combining the sequences of two other D-peptides, RD2 and D3 (sequence: ptlhthnrrrrrrprtrlhthrnr). RD2D3 functions by specifically binding to and eliminating toxic amyloid-beta (Aβ) oligomers, which are considered primary neurotoxic agents responsible for synaptic failure and cognitive decline in Alzheimer's pathology. Due to its all-D-enantiomeric configuration, the peptide is highly resistant to proteolytic degradation, which enhances its stability in the gastrointestinal tract and facilitates blood-brain barrier penetration. Preclinical studies in transgenic mouse models, such as Tg-SwDI and APP/PS1, have demonstrated that oral administration of RD2D3 can significantly improve cognitive performance and reduce behavioral deficits.

Other names

linear RD2D3RD2-D3 tandem peptideRD-2-D3 tandem peptideRD 2-D3 tandem peptide